HSS Study Shows Promising Results for Non-Opioid Pain Reliever in Orthopedic Surgery
Event summary
- HSS study evaluated suzetrigine (JOURNAVX®), a non-opioid pain reliever, in 103 postoperative orthopedic surgery patients.
- 8 patients (7.8%) experienced adverse reactions and discontinued the medication, while 92.2% tolerated it well.
- Suzetrigine targets the Nav1.8 sodium channel, offering more targeted pain relief with fewer side effects compared to traditional pain relievers.
- HSS was an early adopter of suzetrigine, adding it to its formulary in April 2025.
- Ongoing and planned studies will further evaluate suzetrigine's efficacy in various surgical populations.
The big picture
The study highlights a significant shift towards non-opioid pain management in orthopedic surgery, addressing the opioid crisis and the need for safer, more effective pain relief options. HSS's early adoption and ongoing research position it as a leader in advancing musculoskeletal health innovations. The broader industry is watching closely as suzetrigine could set a new standard for postoperative pain management.
What we're watching
- Clinical Efficacy
- How suzetrigine's targeted mechanism will affect its long-term efficacy in reducing opioid dependence post-surgery.
- Market Adoption
- The pace at which suzetrigine will be integrated into standard postoperative pain management protocols.
- Regulatory Landscape
- Whether the FDA will expedite approvals for similar non-opioid pain relievers based on suzetrigine's success.
Related topics